Loading
Latest filing published 09 Dec 2022 for SAB Biotherapeutics, Inc., €96k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Jeffrey G. Spragens is a declared insider at 2 companies (board member); the most frequent names are Asensus Surgical, Inc. and SAB Biotherapeutics, Inc. We count 23 filings; the first trade dates from 31 October 2007 and the latest from 7 December 2022.
No open-market sale appears; the market trades are 16 purchases worth €348k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 2 share grants.
Half of the purchases are above €1,305 and half below.
The newest entry dates from 9 December 2022: a share grant of €96k, in SAB Biotherapeutics, Inc. The last insider purchase was made public on 5 October 2021, 1,845 days ago. The median gap between a trade and its publication by SEC (Form 4) is 3 days. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations